Get the Stockscreener App
16.36
1.18%
0.19
Pre-market:
15.15
-1.21
-7.40%
Benitec Biopharma Inc stock is traded at $16.36, with a volume of 73,759.
It is up +1.18% in the last 24 hours and up +16.61% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$16.17
Open:
$16
24h Volume:
73,759
Relative Volume:
1.47
Market Cap:
$429.46M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.4938
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
-0.97%
1M Performance:
+16.61%
6M Performance:
+20.38%
1Y Performance:
+55.66%
1-Day Range:
$16.00
$16.68
1-Week Range:
$15.20
$16.76
52-Week Range:
$9.10
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
16.36 | 424.47M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma’s BB-301 Receives FDA Fast Track - TipRanks
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug - Investing.com Canada
Benitec (NASDAQ: BNTC) reports 100% responders in Cohort; FDA Fast Track for BB-301 - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors - Yahoo Finance
Is Benitec Biopharma Inc. a candidate for recovery playJuly 2025 Outlook & Weekly Top Gainers Alerts - newser.com
What sentiment indicators say about Benitec Biopharma Inc. stock2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
Full Stock Market News from 2025-11-02 - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) to Share BB-301 OPMD Study Update in Investor Webcast - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire Inc.
Benitec Biopharma Inc. stock trendline breakdownJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Can Benitec Biopharma Inc. rally from current levelsEarnings Recap Report & AI Forecast Swing Trade Picks - newser.com
Benitec Biopharma Inc. recovery potential after sell offBond Market & Stepwise Entry/Exit Trade Alerts - newser.com
Chart based analysis of Benitec Biopharma Inc. trends2025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
Strategies to average down on Benitec Biopharma Inc.2025 Major Catalysts & Fast Gain Swing Trade Alerts - newser.com
Is Benitec Biopharma Inc. stock attractive for long term wealth buildingJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - newser.com
Custom strategy builders for tracking Benitec Biopharma Inc.Weekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Will HYGH stock return to pre crash levels2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Is Benitec Biopharma Inc. stock positioned well for digital economyJuly 2025 Retail & Accurate Trade Setup Notifications - newser.com
Using economic indicators to assess Benitec Biopharma Inc. potentialGDP Growth & Verified High Yield Trade Plans - newser.com
Real time social sentiment graph for Benitec Biopharma Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Why Benitec Biopharma Inc. stock is popular among millennials2025 Top Gainers & Precise Entry and Exit Recommendations - fcp.pa.gov.br
Using AI based signals to follow Benitec Biopharma Inc.Weekly Trend Summary & Community Consensus Stock Picks - newser.com
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):